Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) in the treatment of metastatic colorectal cancer: Systematic review and metanalysis.

e15008 Background: Biological agents have presented variable results in the treatment of metastatic colorectal cancer. This study aim to evaluate the effectiveness and safety of the monoclonal antibodies bevacizumab, cetuximab and panitumumab associated or not to chemotherapy in this scenario. Methods: A systematic review and metanaysis was performed based on observational cohort studies published in the following databases: MEDLINE/ Pubmed, LILACS, COCHRANE Library and EMBASE, up to march 2016. The effectiveness outcomes assessed in this trial were overall survival (OS), progression free survival (PFS), pos-progression survival (PPS), response rate based on RECIST criteria and metastasectomy rate. The safety outcome assessed was adverse events. Review Manager 5.3 software was used to perform the data metanalysis and the Newcastle-Ottawa scale evaluated the methodological quality of the observational trials included. Results: 16 trials were included in this metanalysis, 11 evaluating effectiveness and 8 assessing safety. Their methodological quality were considered moderate according to the Newcastle-Ottawa Scale. Basically, this study compared bevacizumab based therapies with no bevacizumab based therapies, once there was no enough data regarding cetuximab and panitumumab. Overall, the group treated with bevacizumab based therapies did better than those in the no bevacizumab group, with OS mean difference (MD) of 4,41 (95% CI 1.75 to 7.07; p = 0.001; I² = 86%) and PFS MD of 3.19 (95% CI 0.42 to 5.96; p = 0,02 I² = 96%). The PPS MD was also statistically significant (MD = 5.90; 95% CI 2.59 to 9.21; p = 0,0005; I² = 82%). When safety was the outcome concerned, the group treated with bevacizumab had more hypertension and gastrointestinal perforation. There was no statistical difference between the groups regarding others side effects. Conclusions: This study showed a potential benefit in using bevacizumab as a part of the treatment of mCRC. Bevacizumab improved PFS, OS and PPS and these differences were statistically significant. However, the drug also increased treatment related toxicities.

Download Full-text

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2018.12.006 ◽

2019 ◽

Vol 73 ◽

pp. 41-53 ◽

Cited By ~ 21

Author(s):

Gianluca Mauri ◽

Elio Gregory Pizzutilo ◽

Alessio Amatu ◽

Katia Bencardino ◽

Laura Palmeri ◽

...

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Metastatic Colorectal Cancer

Download Full-text

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.05.016 ◽

2015 ◽

Vol 96 (1) ◽

pp. 156-166 ◽

Cited By ~ 32

Author(s):

Filippo Pietrantonio ◽

Chiara Cremolini ◽

Fausto Petrelli ◽

Maria Di Bartolomeo ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Metastatic Colorectal Cancer ◽

Meta Analysis ◽

Wild Type ◽

First Line

Download Full-text

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Annals of Oncology ◽

10.1093/annonc/mdr464 ◽

2012 ◽

Vol 23 (6) ◽

pp. 1518-1525 ◽

Cited By ~ 104

Author(s):

C. Mao ◽

Z.Y. Yang ◽

X.F. Hu ◽

Q. Chen ◽

J.L. Tang

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Metastatic Colorectal Cancer ◽

Meta Analysis ◽

Wild Type ◽

Potential Biomarker ◽

Exon 20

Download Full-text

Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis

Scientific Reports ◽

10.1038/s41598-019-56528-2 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 1

Author(s):

Dedong Cao ◽

Yongfa Zheng ◽

Huilin Xu ◽

Wei Ge ◽

Ximing Xu

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Primary Tumor ◽

Meta Analysis ◽

Tumor Resection ◽

Progression Free Survival ◽

Primary Tumor Resection ◽

Cochrane Library ◽

Colorectal Cancer Patients ◽

Resected Primary Tumor

AbstractIt is not well determined whether primary tumor resection is associated with better outcomes in metastatic colorectal cancer (mCRC) patients treated with bevacizumab. In this meta-analysis, we aimed to assess the prognostic role of primary tumor resection in mCRC treated with bevacizumab. Electronic databases including the Cochrane library, Embase, and Pubmed were searched until April 2018. Clinical studies assessing the influence of primary tumor resection on the efficacy of bevacizumab in patients with mCRC were identified. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Seven studies including 2760 mCRC patients were finally included. The results of the meta-analysis were in favor of bevacizumab to patients with resected primary tumor in terms of OS (HR = 0.50, 95%CI: 0.39–0.64; p < 0.01), and PFS (HR = 0.65, 95%CI: 0.51–0.81; p < 0.01). Administration of bevacizumab in mCRC patients with resected primary tumor had a better OS (HR = 0.65, 95%CI: 0.56–0.74; p < 0.01), when compared to chemotherapy(CT). Adding bevacizumab to mCRC patients without resection of primary tumor also had a better OS (HR = 0.78, 95%CI: 0.65–0.94; p < 0.01) and PFS (HR = 0.71, 95%CI: 0.57–0.88; p < 0.01) compared to chemotherapy alone. In conclusion, mCRC patients with resected primary tumor have better survival than those without surgery of primary tumor when treated with bevacizumab. Primary tumor resection status should be taken into consideration when using bevacizumab in mCRC.

Download Full-text

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

European Journal of Cancer ◽

10.1016/j.ejca.2013.08.008 ◽

2014 ◽

Vol 50 (1) ◽

pp. 40-49 ◽

Cited By ~ 37

Author(s):

A. Lange ◽

A. Prenzler ◽

M. Frank ◽

M. Kirstein ◽

A. Vogel ◽

...

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer

Download Full-text

Prevalence of Dental Caries among Children of Aged 6-12 Years in Tamilnadu - A Systematic Review

International Journal of Science and Healthcare Research ◽

10.52403/ijshr.20211025 ◽

2021 ◽

Vol 6 (4) ◽

pp. 177-185

Author(s):

Suganya. P ◽

Rajmohan. M ◽

Bharathwaj. V. V

Keyword(s):

Systematic Review ◽

Dental Caries ◽

Literature Search ◽

Grey Literature ◽

Public Health Problem ◽

Cochrane Library ◽

Extensive Literature ◽

High Prevalence ◽

Newcastle Ottawa Scale ◽

Ottawa Scale

Background: Dental caries is a serious public health problem in developed as well as developing nations, with high prevalence among children around the world. This systematic review of literature was undertaken to document the prevalence of dental caries. Aims and Objectives: This study aims to evaluate the prevalence of dental caries among children of aged 6-12 years in Tamilnadu by conducting a systematic review. Materials and Method: Studies evaluating the prevalence of dental caries among children of aged 6-12 years in the Tamilnadu were investigated. An extensive literature search was done in the following databases: Prospero, Grey literature, Science Direct, Cochrane library, Wiley online library, Lilacs and PubMed. The articles were retrieved from each database based on the MeSH representation. A modified version of the Newcastle-Ottawa Scale for cross-sectional studies was used for assessment of the quality of the studies. A systematic literature search yielded 1034 publications from the various databases searched. According to the Preferred Reporting Items for systematic Reviews and Meta-Analyses and based on the inclusion and exclusion criteria, the final number of included studies was fifteen. Results: Among the included studies, five studies were carried out in the Chennai district. Erode district was found to have the highest prevalence of dental caries at 89.3%. Conclusion: This review has reported a high prevalence of dental caries in Tamilnadu. None of the states reported prevalence below 30%. The government should identify dental caries as a national priority which requires significant attention. Keywords: Dental caries, Prevalence, Tamilnadu, Newcastle-Ottawa Scale.

Download Full-text

TAS-102 Independent and Combined Therapy in Metastatic Colorectal Cancer

10.21203/rs.3.rs-735929/v1 ◽

2021 ◽

Author(s):

Cheng-Jiang Liu ◽

Ting Hu ◽

Ping Shao ◽

Wu-Yang Chu ◽

Yu Cao ◽

...

Keyword(s):

Colorectal Cancer ◽

Adverse Events ◽

Metastatic Colorectal Cancer ◽

Treatment Plan ◽

Combined Therapy ◽

Meta Analysis ◽

Combined Treatment ◽

Progression Free Survival ◽

Cochrane Library ◽

Free Survival

Abstract Objective To evaluate the effectiveness and safety of TAS-102 in the treatment of metastatic colorectal cancer. Methods The pubmed, web of science, medline, cochrane library databases were searched for the literature on TAS-102 treatment of metastatic colorectal cancer. Extract data such as median Overall Survival (mOS), median Progression-Free Survival (mPFS) and the incidence of adverse events for meta-analysis. Results Our study found that the mOS of patients treated with TAS-102 was 7.74 (95%CI: 6.09–9.85) and the mPFS was 2.91 (95%CI: 2.38–3.57). The mOS in patients treated by TAS-102 Combined with bevacizumab is 10.41 (95%CI: 8.40-12.89) and the mPFS is 4.35 (95%CI: 3.05–6.20). In the control experiment, the patients' mOS and mPFS were improved. TAS-102 + B VS. TAS- 102 (OR = 0.41, 95% CI: 0.18–0.93; OR = 0.72, 95% CI: 0.63–0.83). TAS-102 VS. Placebo(OR = 0.44, 95% CI: 0.29–0.67; OR = 0.51, 95% CI: 0.42–0.62). The incidence of adverse events in combination with bevacizumab will increase. Conclusion TAS-102 single or combined treatment can significantly improve the survival of patients, and drug safety should be considered when formulating a combined treatment plan.

Download Full-text